Compare Neurocrine Biosciences Inc (NBIX) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while First Trust NASDAQ 100 Technology Index Fund trades at $310.02. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, First Trust NASDAQ 100 Technology Index Fund nearer its low. Which is the better fit depends on your goals.
| NBIX | QTEC | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $180.55 | $335.74 |
52-Week Low | $123.10 | $207.03 |
Enterprise Value | $16.49B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
